Key facts
- Pplus Skin Care’s last known valuation is $20.8M (Oct 2025).
- It has raised $4.2M; the latest was Later Stage VC ($1.4M) in Oct 2025.
- Notable investors include Innovate UK, Horizon 2020.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Pplus Skin Care
- ·The full record, as it builds
Funding rounds
No funding rounds for Pplus Skin Care are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pplus Skin Care
Developer of advanced medical technology designed to deliver safe, personalized topical administration of platelet-rich plasma without invasive procedures. The company offers non-invasive PRP application, a patented device for room-temperature platelet preservation, and a collagen-related peptide that supports regeneration, enabling dermatology, hair restoration, orthopedics, dentistry, and wound care practitioners to achieve improved healing and patient comfort.
- Sector
- Healthcare
- HQ
- Salisbury, United Kingdom
- Founded
- 2014
- Employees
- 4
- Website
- pplusmedical.com/
- Ownership
- Privately Held (backing)
Pplus Skin Care doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pplus Skin Care shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pplus Skin Care in its N-PORT filings yet. We sweep new filings monthly.